Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Verastem
Research
AACR: KRAS inhibitors pop in preclinical data debuts
Verastem Oncology, Quanta Therapeutics, Frontier Medicines and more showed off new preclinical data on drugs against the once-”undruggable” target.
Helen Floersh
Apr 11, 2024 4:30am
Verastem bags options on GenFleet RAS programs to grow pipeline
Aug 28, 2023 10:30am
Verastem takes on debt to get RAS tumor program to finish line
Mar 28, 2022 8:30am
Verastem CMO quits 2 weeks into the job
Jan 20, 2021 9:50am
Verastem pens KRAS-focused drug licensing deal with Chugai
Jan 8, 2020 9:20am
Mylan CEO Bresch to exit company after merger—Chutes & Ladders
Aug 2, 2019 9:30am
